{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=37", "query": { "condition": "Cancer, Advanced", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 9813, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T11:51:01.950Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07335497", "title": "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced / Metastatic Solid Tumors" ], "interventions": [ { "name": "CR-001", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "trifluridine and tipiracil", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Gemcitabin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2026-02-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335497" }, { "nct_id": "NCT04626635", "title": "A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "REGN7075", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Platinum-based doublet chemotherapy", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine-tipiracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 548, "start_date": "2020-12-21", "completion_date": "2027-03-05", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 20, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626635" }, { "nct_id": "NCT00913835", "title": "A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Olaratumab", "type": "BIOLOGICAL" }, { "name": "liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 125, "start_date": "2009-06", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2019-09-26", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 6, "location_summary": "Joliet, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 3 more", "locations": [ { "city": "Joliet", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00913835" }, { "nct_id": "NCT00090025", "title": "XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "becatecarin", "type": "DRUG" }, { "name": "5-Fluorouracil Plus Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2004-09", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2009-01-14", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Long Beach, California • Orange, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090025" }, { "nct_id": "NCT06449313", "title": "Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Stage III" ], "interventions": [ { "name": "Cemiplimab-Rwlc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2026-11", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06449313" }, { "nct_id": "NCT00390325", "title": "Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Thyroid Gland Medullary Carcinoma", "Locally Advanced Thyroid Gland Medullary Carcinoma", "Multiple Endocrine Neoplasia Type 2A", "Multiple Endocrine Neoplasia Type 2B", "Recurrent Thyroid Gland Medullary Carcinoma", "Sporadic Thyroid Gland Medullary Carcinoma", "Stage III Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7" ], "interventions": [ { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2006-11-03", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 3, "location_summary": "St Louis, Missouri • Durham, North Carolina • Columbus, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390325" }, { "nct_id": "NCT06463340", "title": "Study of SGR-3515 In Participants With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "SGR-3515", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Schrödinger, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2024-06-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-08-01", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 13, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 9 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463340" }, { "nct_id": "NCT05607550", "title": "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Lung Cancer", "EGFR Exon 20 Mutations" ], "interventions": [ { "name": "furmonertinib 240 mg oral, daily", "type": "DRUG" }, { "name": "furmonertinib 160 mg oral, daily", "type": "DRUG" }, { "name": "platinum-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArriVent BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2023-06-01", "completion_date": "2028-02-15", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 69, "location_summary": "Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05607550" }, { "nct_id": "NCT03724968", "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Advanced Melanoma", "Metastatic Melanoma Stratified by MHC-II Expression" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elizabeth Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-01-17", "completion_date": "2020-05-28", "has_results": true, "last_update_posted_date": "2021-04-20", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03724968" }, { "nct_id": "NCT07700160", "title": "First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "VBC108", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VelaVigo Bio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2026-07-30", "completion_date": "2029-09-17", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-07T11:51:01.950Z", "location_count": 5, "location_summary": "Duarte, California • Grand Rapids, Michigan • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700160" } ] }